Mazeron Renaud, Gouy Sébastien, Chargari Cyrus, Rivin Del Campo Eleonor, Dumas Isabelle, Mervoyer Augustin, Genestie Catherine, Bentivegna Enrica, Balleyguier Corinne, Pautier Patricia, Morice Philippe, Haie-Meder Christine
Department of Radiation Oncology, Gustave Roussy, University of Paris-Saclay, Villejuif, France.
Department of Surgery, Gustave Roussy, University of Paris-Saclay, Villejuif, France.
Radiother Oncol. 2016 Sep;120(3):460-466. doi: 10.1016/j.radonc.2016.07.010. Epub 2016 Aug 2.
Firstly, to evaluate the impact of completion hysterectomy after chemoradiation and image-guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer. Secondly, to assess a potential differential dose-effect relationship for the rectum and bladder according to the realization of hysterectomy.
Two cohorts of patients were identified, differing by the realization of completion hysterectomy. Inclusions were limited to FIGO stage I-II, with no para-aortic involvement. All patients received a combination of pelvic chemoradiation followed by IGABT. Their outcomes and morbidity were reviewed. Log-rank tests were used to compare survivals. Probit analyses were performed to study dose-volume effect relationships.
The two cohorts comprised 54 patients in the completion surgery group and 157 patients in the definitive radiotherapy group. They were well balanced, except for the mean follow-up, significantly longer in the post hysterectomy cohort and the use of PET-CT in the work-up, more frequent in the definitive radiotherapy cohort. Although less local relapses were reported in the hysterectomy group, the 5-year disease-free and overall survival did not differ between groups. The cumulative incidence of severe late morbidity was significantly increased in the hysterectomy cohort: 22.5% versus 6.5% at 5years (p=0.016). Dose-volume effects were observed for the bladder, with the D corresponding with a 10% probability of late severe morbidity urinary events (ED) of 67.8Gy and 91.9Gy in the hysterectomy and definitive radiotherapy cohorts, respectively. A D CTV of 85Gy (planning aim) corresponded with a 93.3% rate of local control in the definitive radiotherapy cohort whereas it corresponded with a 77.3% chance to have a good histologic response (complete response or microscopic residual disease) in the hysterectomy group.
No benefit from completion hysterectomy in terms of overall or disease-free survival rates was observed, which was moreover responsible for an increase of the severe late morbidity. The realization of post-radiation hysterectomy resulted in a shift of the ED of 24.1Gy.
首先,评估在局部晚期宫颈癌中,放化疗及图像引导下的自适应近距离放疗(IGABT)后行子宫全切术的影响。其次,根据子宫全切术的实施情况,评估直肠和膀胱潜在的剂量效应差异关系。
确定了两组患者,区别在于是否实施子宫全切术。纳入标准限于国际妇产科联盟(FIGO)分期I-II期,无腹主动脉旁转移。所有患者均接受盆腔放化疗联合IGABT。回顾了他们的结局和发病率。采用对数秩检验比较生存率。进行概率分析以研究剂量体积效应关系。
子宫全切术组有54例患者,根治性放疗组有157例患者。除平均随访时间外,两组情况均衡,子宫全切术后队列的平均随访时间明显更长,且在检查中使用正电子发射断层扫描(PET-CT)的情况,根治性放疗队列更频繁。尽管子宫全切术组报告的局部复发较少,但两组的5年无病生存率和总生存率无差异。子宫全切术队列中严重晚期并发症的累积发生率显著增加:5年时分别为22.5%和6.5%(p = 0.016)。观察到膀胱存在剂量体积效应,子宫全切术组和根治性放疗队列中,与晚期严重泌尿系统并发症发生概率为10%对应的剂量(ED)分别为67.8Gy和91.9Gy。在根治性放疗队列中,临床靶体积(CTV)剂量为85Gy(计划目标)时局部控制率为93.3%,而在子宫全切术组中,达到良好组织学反应(完全缓解或微小残留疾病)的概率为77.3%。
在总生存率或无病生存率方面,未观察到子宫全切术有任何益处,而且它还导致严重晚期并发症增加。放疗后子宫全切术的实施使ED值偏移了24.1Gy。